Page last updated: 2024-09-05

ly 353381 and eflornithine

ly 353381 has been researched along with eflornithine in 1 studies

Compound Research Comparison

Studies
(ly 353381)
Trials
(ly 353381)
Recent Studies (post-2010)
(ly 353381)
Studies
(eflornithine)
Trials
(eflornithine)
Recent Studies (post-2010) (eflornithine)
7012152,37793268

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fabian, CJ; Kimler, BF1

Reviews

1 review(s) available for ly 353381 and eflornithine

ArticleYear
Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
    Annals of the New York Academy of Sciences, 2001, Volume: 952

    Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Cyclooxygenase Inhibitors; Disease Progression; Eflornithine; Endpoint Determination; Enzyme Inhibitors; Estrogens; Female; Fenretinide; Gonadotropin-Releasing Hormone; Humans; Hyperplasia; Isoflavones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Polyamines; Precancerous Conditions; Protein-Tyrosine Kinases; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Uterine Neoplasms

2001